Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

In 2008 alone, Cabilly II generated at least $237 million for the company. “It's not even close in terms of whether it was worth it for Genentech,” says Clark. The patent office initially ...

The company is offering the university up to $13 million in development and commercial milestone payments and a share in any resulting royalties. Genentech, of South San Francisco, California ...

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and ...

It also comes after a pledge by the company to plough savings from a cost-reduction drive back into its pipeline. The three platform deals are long-term bets, but broaden Genentech’s drug ...

and is coming up to a two-decade anniversary at the Roche/Genentech group. She also took control of the company during Hardy’s recent sabbatical, a longstanding policy at the biotech unit that ...

The potential blockbuster drug was approved by the agency more than a month before its scheduled decision date. A potential blockbuster cancer drug developed by Genentech Inc. and parent company ...

The company, valued at $6.2 billion in October 2021, has approximately 1,700 employees, according to a LinkedIn estimate, ...

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account. We offer one free story view per month. If you ...

https://www.tipranks.com/news/the-fly/stryker-price-target-raised-to-400-from-360-at-canaccord Genentech, a member of the Roche (RHHBY), announced topline one-year ...

Evrysdi generated CHF 1.4bn ($1.64bn) in 2023 for Genentech, as per the company’s annual report, with projections from GlobalData estimating $2.8bn in revenue by 2030. Evrysdi’s main ...

Additionally, Recursion expanded its collaboration with Google Cloud to enhance its drug discovery platform, and optioned its first neuroscience phenomap to Roche-Genentech in a deal potentially ...